Chicago Partners Investment Group LLC trimmed its stake in Ascendis Pharma A/S (NASDAQ:ASND – Get Rating) by 15.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,781 shares of the biotechnology company’s stock after selling 1,465 shares during the period. Chicago Partners Investment Group LLC’s holdings in Ascendis Pharma A/S were worth $669,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its position in shares of Ascendis Pharma A/S by 17.8% in the 1st quarter. SG Americas Securities LLC now owns 942 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 142 shares in the last quarter. Captrust Financial Advisors grew its stake in Ascendis Pharma A/S by 3,069.7% during the 1st quarter. Captrust Financial Advisors now owns 1,046 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,013 shares during the last quarter. Icapital Wealth LLC purchased a new position in Ascendis Pharma A/S during the 1st quarter worth $166,000. Guggenheim Capital LLC grew its stake in Ascendis Pharma A/S by 7.2% during the 1st quarter. Guggenheim Capital LLC now owns 2,008 shares of the biotechnology company’s stock worth $236,000 after buying an additional 135 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Ascendis Pharma A/S during the 1st quarter worth $237,000.
Ascendis Pharma A/S Price Performance
Shares of Ascendis Pharma A/S stock opened at $106.61 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 9.66 and a quick ratio of 8.78. The business has a 50 day simple moving average of $92.62 and a two-hundred day simple moving average of $96.70. The stock has a market capitalization of $6.07 billion, a P/E ratio of -13.51 and a beta of 0.66. Ascendis Pharma A/S has a 12 month low of $61.58 and a 12 month high of $172.65.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the company. SVB Leerink dropped their target price on Ascendis Pharma A/S from $174.00 to $168.00 and set an “outperform” rating on the stock in a research note on Thursday, August 11th. Morgan Stanley dropped their price target on Ascendis Pharma A/S from $152.00 to $148.00 and set an “overweight” rating on the stock in a research note on Thursday, August 11th. Berenberg Bank reiterated a “buy” rating and set a $166.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, August 30th. Finally, Oppenheimer dropped their price target on Ascendis Pharma A/S from $154.00 to $144.00 and set an “outperform” rating on the stock in a research note on Thursday, August 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $154.10.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.
- Get a free copy of the StockNews.com research report on Ascendis Pharma A/S (ASND)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- Four Cheap Stocks With Interesting Insider Activity
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.